FDA NMN Policy - March 2023 Update
In March 2023, two of the largest supplement and natural products trade organizations filed a citizen's petition with the FDA asking that they change their position on NMN. The Natural Products Association (NPA) and the Alliance for Natural Health (ANH) asked the FDA to:
- Determine nicotinamide mononucleotide (NMN) is not excluded from the definition of a dietary supplement under 21 U.S.C. §321(ff)(3)(B);
- Commit to exercising enforcement discretion in connection with the marketing and selling of NMN in or as a dietary supplement; or
- In the alternative, recommend the Secretary of Health and Human Services (HHS) issue a regulation after notice comment, finding NMN would be lawful.